X-Chem
X-Chem is a privately held biotechnology company that provides integrated small-molecule drug discovery services to pharmaceutical and biotech clients using a proprietary DNA-Encoded Library (DEL) platform, medicinal chemistry, computational sciences, and AI/ML.
- Company typePrivate
- Founded2009
- HeadquartersWaltham, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What X-Chem does
X-Chem is a privately held biotechnology company founded in 2009 and headquartered in Waltham, Massachusetts, that operates as an integrated small-molecule drug discovery partner to pharmaceutical and biotechnology companies. The company's core technology is a proprietary DNA-Encoded Library (DEL) platform built around libraries exceeding 100 billion compounds, supplemented by medicinal and synthetic chemistry, computational sciences, and AI/ML capabilities under its Chemomics approach. X-Chem delivers discovery outcomes through tiered engagement models: DELcore (full-service discovery partnerships), DELflex (flexible DEL access bundles), and DELability (low-cost tractability assessments), alongside modular milestone-driven programs branded HitBuilder, LeadBuilder, and CandidateBuilder that span hit identification through candidate nomination.
The company monetizes its platform through four revenue streams: fee-for-service drug discovery programs, strategic collaborations with biopharma partners, DEL platform enablement and technology transfer (licensing/royalty economics), and direct sales of ReadiDEL libraries and ReadiBLOX building blocks to partners conducting screening internally. Customer segments span large pharmaceutical companies (Roche, AstraZeneca, AbbVie), mid-market biotech (Enko, Tonix, Kymera), early-stage biotech (Montara Therapeutics, Cube Biotech), academic core facilities, and use-case-specific segments such as neuroscience- and oncology-focused companies. X-Chem reports cumulative outputs of 18 clinical candidates since 2016, 100+ licensed programs, 700+ novel series, >200 billion molecules screened, and >30 challenging target classes addressed. The company operates approximately 200 professional and research staff across Waltham, Montreal, and Budapest, and owns three wholly owned subsidiaries acquired in 2021: IntelliSyn Pharma (medicinal chemistry), ComInnex (European synthetic chemistry), and Glamorous AI (DEL-powered AI services).
X-Chem firmographics
Firmographics- Name
- X-Chem
- Legal name
- X-Chem, Inc.
- Website
- https://x-chemrx.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- X-Chem is a privately held biotechnology company that provides integrated small-molecule drug discovery services to pharmaceutical and biotech clients using a proprietary DNA-Encoded Library (DEL) platform, medicinal chemistry, computational sciences, and AI/ML.
- Ownership category
- akta.pro rank
X-Chem industry classification
Industry- Product category
- Contract Drug Discovery Services
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where X-Chem is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
X-Chem business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Drug Discovery Services: Fee-for-service drug discovery programs including DEL screening, medicinal chemistry, and computational sciences structured as modular, milestone-driven project engagements (HitBuilder, LeadBuilder, CandidateBuilder)
- Strategic Collaborations: Deeply integrated discovery partnerships with biopharma companies providing exclusive or shared discovery outcomes
- DEL Platform Enablement: Technology transfer programs enabling partners to conduct DEL screening internally using ReadiDEL libraries and X-Chem's informatics tools
- Research Products: Sale of ReadiDEL libraries and ReadiBLOX building blocks for internal DEL screening operations
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | DELcore - Full-service discovery partnership |
| Subscription | Annual | DELflex - Flexible DEL access bundle |
| Usage-based | Pay-as-you-go | DELability - Feasibility assessment |
| Other | Multi-year contract | Platform Enablement - Technology transfer |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
X-Chem product offering
Product offeringCore offering
X-Chem provides DNA-encoded library (DEL) screening-based drug discovery services combined with medicinal chemistry, computational sciences, and AI/ML capabilities. The company offers modular milestone-driven programs (HitBuilder, LeadBuilder, CandidateBuilder), fee-for-service packages (DELcore, DELflex, DELability), platform enablement technology transfers, and research products (ReadiDEL libraries, ReadiBLOX building blocks) to help pharmaceutical and biotechnology companies identify and optimize small molecule drug candidates from hit identification through clinical candidate nomination.
Product overview
X-Chem is a DEL technology pioneer offering an integrated drug discovery platform built around DNA-encoded library (DEL) screening as the core engine. The platform comprises multiple tiers (DELcore, DELflex, DELability) for hit identification, augmented by HITMiner AI/ML analytics and the Chemomics approach for data-driven decision making. Downstream services include ReadiDEL and ReadiBLOX research products, Computational Sciences, and Medicinal & Synthetic Chemistry. Modular programs (HitBuilder, LeadBuilder, CandidateBuilder) provide milestone-driven pathways from screening through candidate nomination. The company also offers Platform Enablement for partners building internal DEL capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- ReadiDEL: DNA-encoded library products ready for screening, including over 40 specialized libraries totaling more than 15 billion compounds
- ReadiBLOX
- HitBuilder
- LeadBuilder
- CandidateBuilder
- Chemomics
Products and services
- DELcore
- DELflex
- DELability
- Covalent Irreversible DEL
- ReadiDEL
- ReadiBLOX
- Chemomics
- Computational Sciences
- Medicinal & Synthetic Chemistry
- HitBuilder
- LeadBuilder
- CandidateBuilder
Quantifiable outcome
- 18 clinical candidates since 2016
- +6 more outcomes
Companies that use X-Chem
Customer profileNamed customers9 records
Segments5 records
Ideal customer profiles3 records
X-Chem technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature11 records
X-Chem partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered flagship, core and supporting.
- Charles River LaboratoriesflagshipStrategic collaboration to enhance hit identification capabilities for drug discovery. Combines Charles River's existing drug discovery services with X-Chem's DNA-encoded library technology to support biopharma research and accelerate therapeutic discovery. Partnership aims to support hundreds of discovery programs.
- ComInnexcoreX-Chem acquired ComInnex, a European provider of synthetic chemistry services and technologies to support early-stage drug discovery. Acquisition expanded X-Chem's global capacity, service offerings, and expertise in innovative chemistry solutions for biopharma clients.
- Glamorous AIcoreX-Chem acquired Glamorous AI, adding the industry's only DEL-powered AI service for early-stage drug discovery to its portfolio.
- IntelliSyn PharmacoreX-Chem acquired IntelliSyn in January 2021, establishing hit-to-lead service capabilities including medicinal chemistry.
- Montara TherapeuticscoreCollaboration for neurological disease drug discovery. Leveraging brain-specific pharmacology platform, Montara works with X-Chem for next-generation therapies including dementia treatments. Based on successful prior collaboration with Mitokinin (acquired by AbbVie in 2023).
- RochecoreDEL enablement partnership allowing Roche to operate DEL synthesis and screening internally. Roche/Genentech report indicated DEL accounted for ~30% of novel internally generated leads in 2019.
- AstraZenecacoreLong-standing DEL collaboration with X-Chem screening many targets from AZ portfolio. Technology transfer enabled AZ to operate DEL synthesis and screening internally, providing flexibility for early-stage research deployment.
- EnkocoreMulti-year collaboration culminating in successful technology enablement, empowering Enko to operate DEL platform internally. Projects have successfully progressed to include many high-potential products.
- Structural Genomics Consortium (SGC)coreCollaboration on ligand generation for WD40 repeat-containing proteins. Large-scale multiplexed DEL selection followed by ML model training identified active compounds for 7 out of 16 previously unliganded targets.
- GooglecoreCollaboration using DEL data for machine learning published in August 2020. Combined DEL screening with ML for target class ligandability evaluation.
- Relay TherapeuticscoreCollaboration on WD40 repeat protein targets using DEL selection and machine learning approaches.
- SymeressupportingCollaboration on discovery and optimization of macrocycles targeting Mcl-1 oncology target, demonstrating acceptable permeability and high potency.
- AbbViecoreCollaboration on IL-17 inhibitors with DEL-generated SAR and co-crystal structural information leading to compound with good PK properties and potent animal model efficacy.
- ArbutussupportingCollaboration on development of noncovalent inhibitors for SARS-CoV-2 Mpro using DEL screening and macrocyclization strategy, achieving 10-fold potency improvement.
- Texas A&M UniversitysupportingDEL screening collaboration where hits demonstrated in vivo efficacy in mouse model for tuberculosis.
Scale indicators13 records
Recent moves7 records
Expansion highlights5 records
X-Chem competitors and assessment
Company assessmentEmerging players
- Carmot Therapeutics / BeBetter MedChem CROs: Smaller discovery CROs focused on fragment- and structure-based hit identification for biotech. Representative of the emerging-player tier of CROs that compete with X-Chem's HitBuilder and LeadBuilder programs on price for early-stage biotech.
- Domainex: Domainex is a UK-based CRO offering integrated drug discovery including hit identification, medicinal chemistry and computational services. Comparable to X-Chem's integrated service model for biotech clients, particularly in the European market.
Direct peers
- Symeres: Symeres is a European CRO specializing in medicinal chemistry, custom synthesis and discovery services. Comparable to X-Chem's medicinal and synthetic chemistry offering and an existing collaboration partner on macrocycle discovery programs.
- HitGen: HitGen is the original DNA-encoded library (DEL) pioneer and operates a directly comparable DEL screening and small-molecule discovery services business, including DEL library products and partnered programs with global pharma. Most direct competitor to X-Chem's core DEL platform.
- Philochem: Philochem is a Swiss-based DEL screening provider and one of the early commercial DEL technology developers. Competes head-to-head with X-Chem in DEL-based hit identification for European pharma and biotech clients.
- Vipergen: Vipergen is a DEL-technology focused CRO offering DNA-encoded library screening and hit identification services to pharma and biotech. Closely comparable technology stack and customer base to X-Chem's DELcore and DELflex offerings.
Broad incumbents
- Evotec: Evotec is a global drug discovery CRO offering end-to-end discovery and development services including DEL-based screening. Overlaps with X-Chem across hit identification, medicinal chemistry and integrated drug discovery but at much broader scale.
- Nuevolution (Amgen): Nuevolution was an early DEL competitor acquired by Amgen in 2016; its DEL capability is now embedded inside Amgen's internal discovery engine. Relevant comparable because it demonstrates how DEL platforms are absorbed into large-pharma in-house operations, a key dynamic for X-Chem.
- WuXi AppTec (HitSplice / DEL services): WuXi AppTec is a global CRO/CDMO offering DEL-enabled drug discovery alongside a much broader portfolio of chemistry, biology and manufacturing services. Overlaps with X-Chem in DEL screening but typically priced more aggressively and bundled with downstream development services.
- Charles River Laboratories: Charles River is a large CRO with an end-to-end drug discovery and safety assessment portfolio and is now X-Chem's strategic distribution partner. Overlaps with X-Chem on early discovery services but also serves as a route to market for X-Chem's DEL platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
X-Chem social profiles
Digital presenceX-Chem financial estimates
Financial estimateRevenue estimate
Valuation estimate
X-Chem leadership team
Management profileNumber of profiles
Profiles10 records
X-Chem subsidiaries and ownership
Company hierarchySubsidiaries3 records
X-Chem funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
X-Chem M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about X-Chem
What does X-Chem do?
X-Chem provides DNA-encoded library (DEL) screening-based drug discovery services combined with medicinal chemistry, computational sciences, and AI/ML capabilities. The company offers modular milestone-driven programs (HitBuilder, LeadBuilder, CandidateBuilder), fee-for-service packages (DELcore, DELflex, DELability), platform enablement technology transfers, and research products (ReadiDEL libraries, ReadiBLOX building blocks) to help pharmaceutical and biotechnology companies identify and optimize small molecule drug candidates from hit identification through clinical candidate nomination.
Is X-Chem a public or private company?
X-Chem is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was X-Chem founded?
X-Chem was founded in 2009. It employs 51 to 100 people.
Where is X-Chem based?
X-Chem is headquartered in Waltham, United States, in the North America region.
How does X-Chem make money?
Four revenue lines are on record. Drug Discovery Services are the primary driver. The others are strategic Collaborations, DEL Platform Enablement and research Products.
Who are X-Chem's main competitors?
Emerging players on record are Carmot Therapeutics / BeBetter MedChem CROs and Domainex. Direct peers are Symeres, HitGen, Philochem and Vipergen. Broad incumbents are Evotec, Nuevolution (Amgen), WuXi AppTec (HitSplice / DEL services) and Charles River Laboratories.
Does X-Chem have an API?
No public API is recorded for X-Chem.
What industry is X-Chem in?
X-Chem's product category is Contract Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 334516 and its SIC code is 8731.